Douglas S. Krafte

Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC.

The Biophysical Society specializes in the characterization of molecular structure, measurement of molecular properties, and observation of molecular behavior. The non-profit company is based in Bethesda, MD. The company utilizes a variety of biophysical techniques to study molecules in crystals, solutions, cells, and organisms, providing information about electronic structure, size, shape, dynamics, polarity, and modes of interaction of biological molecules.

The Society for Neuroscience is an organization with over 36,000 members in more than 95 countries. The non-profit company is based in Washington. The organization also engages in science advocacy and public policy, including an annual Capitol Hill Day, and has various public outreach efforts, such as the interactive collection of public-facing resources on BrainFacts.org. It was founded in 1969 and offers year-round programming, including the publication of two scientific journals, professional development resources, and career training through Neuronline.

Icagen-T, Inc. engages in development of pharmaceutical drugs. The company is headquartered in Oro Valley, AZ.

Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC.

Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA.